The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

Innovative research approaches are therefore urgently needed to achieve long-term progress in prevention and ...

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...

Epigenetics are one of life's primary drivers of adaptations. They are why human beings who live at high altitude have more ...

BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early-to-mid stage trial of its malaria vaccine.

"Our research shows that PfSnf2L is essential for P. falciparum to dynamically adjust gene expression," said Maria Theresia Watzlowik of the University of Regensburg in Germany, the first author ...

P. falciparum is introduced into the body via a mosquito bite. The parasite grows and multiplies first in the liver, then uses human red blood cells as a nursery in which to replicate and release ...

BioNTech's early-to-mid stage trial of an experimental malaria vaccine has been put on a clinical hold by the U.S. Food and Drug Administration (USFDA), the drugmaker said in a filing.The trial ...

In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a ...

"Our research shows that PfSnf2L is essential for P. falciparum to dynamically adjust gene expression," explains Maria Theresia Watzlowik, lead author of the study. "The unique sequence and ...